| 1 | Severe Impact of Omeprazole Timing on pH-Sensitive Dasatinib Absorption: Unveiling Substantial Drug–Drug Interaction | 1.3 | 9 | Citations (PDF) |
| 2 | A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats | 3.3 | 19 | Citations (PDF) |
| 3 | Mapping the polar metabolome in Huh-7 liver cancer cells reveal the role of atorvastatin in enhancing chemotherapeutic efficacy of doxorubicin | 2.2 | 0 | Citations (PDF) |
| 4 | Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins | 1.6 | 13 | Citations (PDF) |
| 5 | Ammonium bicarbonate buffers combined with hybrid surface technology columns improve the peak shape of strongly tailing lipids | 4.5 | 5 | Citations (PDF) |
| 6 | Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform | 1.0 | 15 | Citations (PDF) |
| 7 | Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I Protein | 2.6 | 4 | Citations (PDF) |
| 8 | Development and validation of LC-MS/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide (ARV-110) and vepdegestrant (ARV-471) | 2.2 | 19 | Citations (PDF) |
| 9 | Melatonin mitigates chemotherapy-induced small intestinal atrophy in rats and reduces cytotoxicity in murine intestinal organoids | 1.6 | 7 | Citations (PDF) |
| 10 | Influence of extracellular matrix composition on tumour cell behaviour in a biomimetic in vitro model for hepatocellular carcinoma | 2.8 | 36 | Citations (PDF) |
| 11 | Novel food drug interaction mechanism involving acyclovir, chitosan and endogenous mucus | 0.3 | 7 | Citations (PDF) |
| 12 | Review on the effect of chemotherapy on the intestinal barrier: Epithelial permeability, mucus and bacterial translocation | 5.7 | 82 | Citations (PDF) |
| 13 | Anakinra and dexamethasone treatment of idarubicin-induced mucositis and diarrhoea in rats | 2.1 | 9 | Citations (PDF) |
| 14 | Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug–drug interactions | 1.6 | 13 | Citations (PDF) |
| 15 | Quantitative imaging of doxorubicin diffusion and cellular uptake in biomimetic gels with human liver tumor cells | 3.8 | 14 | Citations (PDF) |
| 16 | Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review | 3.5 | 62 | Citations (PDF) |
| 17 | Chemotherapeutics Combined with Luminal Irritants: Effects on Small-Intestinal Mannitol Permeability and Villus Length in Rats | 3.3 | 11 | Citations (PDF) |
| 18 | Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma | 3.5 | 66 | Citations (PDF) |
| 19 | Protective Effects of Melatonin and Misoprostol against Experimentally Induced Increases in Intestinal Permeability in Rats | 3.3 | 6 | Citations (PDF) |
| 20 | Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research | 4.4 | 23 | Citations (PDF) |
| 21 | Drug diffusion in biomimetic hydrogels: importance for drug transport and delivery in non-vascular tumor tissue | 3.5 | 14 | Citations (PDF) |
| 22 | Does the choice of applied physiologically-based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction | 1.6 | 20 | Citations (PDF) |
| 23 | Effect of liver stiffness on hepatocellular carcinoma phenotype in a biometric 3D model | 7.6 | 0 | Citations (PDF) |
| 24 | Inhibiting IRE1a-endonuclease activity potentiates the effect of doxorubicin in hepatocellular carcinoma | 7.6 | 0 | Citations (PDF) |
| 25 | Orthogonality in Principal Component Analysis Allows the Discovery of Lipids in the Jejunum That Are Independent of Ad Libitum Feeding | 2.7 | 5 | Citations (PDF) |
| 26 | Evaluation and validation of chemotherapy-specific diarrhoea and histopathology in rats | 2.1 | 9 | Citations (PDF) |
| 27 | The progression of doxorubicin-induced intestinal mucositis in rats | 2.3 | 17 | Citations (PDF) |
| 28 | People also looked at | 1.7 | 3 | Citations (PDF) |
| 29 | Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies | 2.7 | 132 | Citations (PDF) |
| 30 | Anthracyclins Increase PUFAs: Potential Implications in ER Stress and Cell Death | 3.5 | 21 | Citations (PDF) |
| 31 | Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats | 8.9 | 29 | Citations (PDF) |
| 32 | In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma | 3.5 | 67 | Citations (PDF) |
| 33 | Melatonin-Activated Receptor Signaling Pathways Mediate Protective Effects on Surfactant-Induced Increase in Jejunal Mucosal Permeability in Rats | 3.3 | 10 | Citations (PDF) |
| 34 | Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma | 3.3 | 47 | Citations (PDF) |
| 35 | Prevention of Rat Intestinal Injury with a Drug Combination of Melatonin and Misoprostol | 3.3 | 11 | Citations (PDF) |
| 36 | Pulmonary drug absorption and systemic exposure in human: Predictions using physiologically based biopharmaceutics modeling | 3.3 | 28 | Citations (PDF) |
| 37 | Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity | 1.6 | 30 | Citations (PDF) |
| 38 | The Critical Role of Passive Permeability in Designing Successful Drugs | 2.3 | 97 | Citations (PDF) |
| 39 | Drug Absorption Parameters Obtained Using the Isolated Perfused Rat Lung Model Are Predictive of Rat In Vivo Lung Absorption | 2.2 | 23 | Citations (PDF) |
| 40 | Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat | 4.4 | 18 | Citations (PDF) |
| 41 | Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective | 3.3 | 32 | Citations (PDF) |
| 42 | The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin | 4.4 | 22 | Citations (PDF) |
| 43 | Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations | 1.7 | 17 | Citations (PDF) |
| 44 | Lipiodol-based emulsions used for transarterial chemoembolization and drug delivery: Effects of composition on stability and product quality | 2.6 | 22 | Citations (PDF) |
| 45 | Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile | 2.9 | 51 | Citations (PDF) |
| 46 | Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches | 4.4 | 224 | Citations (PDF) |
| 47 | Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model | 3.4 | 28 | Citations (PDF) |
| 48 | Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited | 1.6 | 78 | Citations (PDF) |
| 49 | Pulmonary absorption – estimation of effective pulmonary permeability and tissue retention of ten drugs using an rat model and computational analysis | 3.3 | 46 | Citations (PDF) |
| 50 | Reply to “Comment on ‘In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma’” | 3.4 | 1 | Citations (PDF) |
| 51 | Porcine and Human In Vivo Simulations for Doxorubicin-Containing Formulations Used in Locoregional Hepatocellular Carcinoma Treatment | 2.2 | 11 | Citations (PDF) |
| 52 | Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded ‘21st Century BA/BE’ project | 4.0 | 47 | Citations (PDF) |
| 53 | Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions | 2.1 | 29 | Citations (PDF) |
| 54 | A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition | 3.4 | 22 | Citations (PDF) |
| 55 | In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma | 3.4 | 37 | Citations (PDF) |
| 56 | Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs. | 2.5 | 7 | Citations (PDF) |
| 57 | Regional Intestinal Permeability in Rats: A Comparison of Methods | 3.4 | 46 | Citations (PDF) |
| 58 | Preclinical Effect of Absorption Modifying Excipients on Rat Intestinal Transport of Model Compounds and the Mucosal Barrier Marker 51Cr-EDTA | 3.4 | 34 | Citations (PDF) |
| 59 | In Vivo Mechanisms of Intestinal Drug Absorption from Aprepitant Nanoformulations | 3.4 | 57 | Citations (PDF) |
| 60 | An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer | 3.5 | 8 | Citations (PDF) |
| 61 | Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs | 1.6 | 14 | Citations (PDF) |
| 62 | IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results | 3.5 | 65 | Citations (PDF) |
| 63 | IMI – oral biopharmaceutics tools project – evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds | 3.5 | 37 | Citations (PDF) |
| 64 | IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing performance across different compound classes | 3.5 | 43 | Citations (PDF) |
| 65 | In Vitro Release Mechanisms of Doxorubicin From a Clinical Bead Drug-Delivery System | 2.6 | 44 | Citations (PDF) |
| 66 | Regional Intestinal Permeability of Three Model Drugs in Human | 3.4 | 66 | Citations (PDF) |
| 67 | Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms | 3.4 | 36 | Citations (PDF) |
| 68 | Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption | 2.2 | 20 | Citations (PDF) |
| 69 | Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide | 3.4 | 33 | Citations (PDF) |
| 70 | Human in Vivo Regional Intestinal Permeability: Quantitation Using Site-Specific Drug Absorption Data | 3.4 | 62 | Citations (PDF) |
| 71 | Direct In Vivo Human Intestinal Permeability (Peff) Determined with Different Clinical Perfusion and Intubation Methods | 2.6 | 113 | Citations (PDF) |
| 72 | Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy | 1.5 | 96 | Citations (PDF) |
| 73 | Treatment of Intermediate Stage Hepatocellular Carcinoma: A Review of Intrahepatic Doxorubicin Drug-Delivery Systems | 2.2 | 28 | Citations (PDF) |
| 74 | High-resolution mass spectrometric investigation of the phase I and II metabolites of finasteride in pig plasma, urine and bile | 1.0 | 6 | Citations (PDF) |
| 75 | Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs | 3.5 | 6 | Citations (PDF) |
| 76 | Regional intestinal drug permeation: Biopharmaceutics and drug development | 3.5 | 88 | Citations (PDF) |
| 77 | methods for drug absorption – Comparative physiologies, model selection, correlations with methods (IVIVC), and applications for formulation/API/excipient characterization including food effects | 3.5 | 258 | Citations (PDF) |
| 78 | Evaluation of the use of Classical Nucleation Theory for predicting intestinal crystalline precipitation of two weakly basic BSC class II drugs | 3.5 | 21 | Citations (PDF) |
| 79 | The Effects of Lipiodol and Cyclosporin A on the Hepatobiliary Disposition of Doxorubicin in Pigs | 3.4 | 10 | Citations (PDF) |
| 80 | Human in Vivo Regional Intestinal Permeability: Importance for Pharmaceutical Drug Development | 3.4 | 76 | Citations (PDF) |
| 81 | Pharmacokinetics of an Injectable Modified-Release 2-Hydroxyflutamide Formulation in the Human Prostate Gland Using a Semiphysiologically Based Biopharmaceutical Model | 3.4 | 19 | Citations (PDF) |
| 82 | Investigation of Hepatobiliary Disposition of Doxorubicin Following Intrahepatic Delivery of Different Dosage Forms | 3.4 | 24 | Citations (PDF) |
| 83 | Passive Lipoidal Diffusion and Carrier-Mediated Cell Uptake Are Both Important Mechanisms of Membrane Permeation in Drug Disposition | 3.4 | 125 | Citations (PDF) |
| 84 | Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments | 1.5 | 17 | Citations (PDF) |
| 85 | Combined in Vitro–in Vivo Approach To Assess the Hepatobiliary Disposition of a Novel Oral Thrombin Inhibitor | 3.4 | 14 | Citations (PDF) |
| 86 | In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: Application of the mechanistic absorption model GI-Sim | 3.5 | 162 | Citations (PDF) |
| 87 | Carbon Dioxide-Mediated Generation of Hybrid Nanoparticles for Improved Bioavailability of Protein Kinase Inhibitors | 2.5 | 59 | Citations (PDF) |
| 88 | Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors | 2.2 | 235 | Citations (PDF) |
| 89 | Clinical Pharmacokinetics of Atorvastatin | 2.2 | 424 | Citations (PDF) |
| 90 | Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery | 1.0 | 12 | Citations (PDF) |
| 91 | Complexity of Motor Response to Different Doses of Duodenal Levodopa Infusion in Parkinson Disease | 0.8 | 25 | Citations (PDF) |
| 92 | Binding Processes Determine the Stereoselective Intestinal and Hepatic Extraction of Verapamil in Vivo | 3.4 | 5 | Citations (PDF) |
| 93 | The Fraction Dose Absorbed, in Humans, and High Jejunal Human Permeability Relationship | 3.4 | 76 | Citations (PDF) |
| 94 | In Vivo Dog Intestinal Precipitation of Mebendazole: A Basic BCS Class II Drug | 3.4 | 46 | Citations (PDF) |
| 95 | The Pharmacokinetics and Hepatic Disposition of Repaglinide in Pigs: Mechanistic Modeling of Metabolism and Transport | 3.4 | 25 | Citations (PDF) |
| 96 | Biliary Excretion of Ximelagatran and Its Metabolites and the Influence of Erythromycin Following Intraintestinal Administration to Healthy Volunteers | 1.3 | 4 | Citations (PDF) |
| 97 | Human jejunal effective permeability and its correlation with preclinical drug absorption models. | 2.5 | 129 | Citations (PDF) |
| 98 | A Residence-Time Distribution Analysis of the Hydrodynamics within the Intestine in Man during a Regional Single-pass Perfusion with Loc-I-Gut: In-vivo Permeability Estimation | 2.5 | 21 | Citations (PDF) |
| 99 | Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. | 2.5 | 59 | Citations (PDF) |
| 100 | The Effect of a Drug-delivery System Consisting of Soybean Phosphatidyl Choline and Medium-chain Monoacylglycerol on the Intestinal Permeability of Hexarelin in the Rat | 2.5 | 16 | Citations (PDF) |
| 101 | Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats. | 2.5 | 30 | Citations (PDF) |
| 102 | The absence of stereoselective P-glycoprotein-mediated transport of R/S-verapamil across the rat jejunum. | 2.5 | 16 | Citations (PDF) |
| 103 | Concentration- and Region-dependent Intestinal Permeability of Fluvastatin in the Rat | 2.5 | 14 | Citations (PDF) |
| 104 | Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans | 3.5 | 57 | Citations (PDF) |
| 105 | Effects of Ketoconazole on the In Vivo Biotransformation and Hepatobiliary Transport of the Thrombin Inhibitor AZD0837 in Pigs | 2.1 | 7 | Citations (PDF) |
| 106 | Optimal Experimental Design for Assessment of Enzyme Kinetics in a Drug Discovery Screening Environment | 2.1 | 6 | Citations (PDF) |
| 107 | In Vivo Investigation in Pigs of Intestinal Absorption, Hepatobiliary Disposition, and Metabolism of the 5α-Reductase Inhibitor Finasteride and the Effects of Coadministered Ketoconazole | 2.1 | 15 | Citations (PDF) |
| 108 | Circadian Rhythmicity in Levodopa Pharmacokinetics in Patients With Parkinson Disease | 0.8 | 26 | Citations (PDF) |
| 109 | Investigations of the In-vitro Metabolism of Three Opioid Tetrapeptides by Pancreatic and Intestinal Enzymes | 2.5 | 9 | Citations (PDF) |
| 110 | Effects of cholesterol and model transmembrane proteins on drug partitioning into lipid bilayers as analysed by immobilized-liposome chromatography | 2.5 | 9 | Citations (PDF) |
| 111 | Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine | 2.5 | 25 | Citations (PDF) |
| 112 | The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans | 2.5 | 27 | Citations (PDF) |
| 113 | Intestinal drug absorption and bioavailability: beyond involvement of single transport function. | 2.5 | 13 | Citations (PDF) |
| 114 | The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension† | 2.5 | 164 | Citations (PDF) |
| 115 | Hepatic Disposition of Ximelagatran and Its Metabolites in Pig; Prediction of the Impact of Membrane Transporters Through a Simple Disposition Model | 2.5 | 3 | Citations (PDF) |
| 116 | Predicting Intestinal Precipitation—A Case Example for a Basic BCS Class II Drug | 2.5 | 123 | Citations (PDF) |
| 117 | Gastrointestinal metabolism of a vegetable-oil emulsion in healthy subjects. | 3.4 | 27 | Citations (PDF) |
| 118 | Effect of a Single Gemfibrozil Dose on the Pharmacokinetics of Rosuvastatin in Bile and Plasma in Healthy Volunteers | 1.3 | 15 | Citations (PDF) |
| 119 | High-Permeability Criterion for BCS Classification: Segmental/pH Dependent Permeability Considerations | 3.4 | 93 | Citations (PDF) |
| 120 | The Multiple Depletion Curves Method Provides Accurate Estimates of Intrinsic Clearance (CLint), Maximum Velocity of the Metabolic Reaction (Vmax), and Michaelis Constant (Km): Accuracy and Robustness Evaluated through Experimental Data and Monte Carlo Simulations | 2.1 | 36 | Citations (PDF) |
| 121 | Different Effects of Ketoconazole on the Stereoselective First-Pass Metabolism of R/S-Verapamil in the Intestine and the Liver: Important for the Mechanistic Understanding of First-Pass Drug-Drug Interactions | 2.1 | 16 | Citations (PDF) |
| 122 | Identification of Finasteride Metabolites in Human Bile and Urine by High-Performance Liquid Chromatography/Tandem Mass Spectrometry | 2.1 | 22 | Citations (PDF) |
| 123 | The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men | 3.5 | 35 | Citations (PDF) |
| 124 | Impact of carriers in oral absorption: Permeation across Caco-2 cells for the organic anions estrone-3-sulfate and glipizide | 3.5 | 23 | Citations (PDF) |
| 125 | Online capillary solid phase extraction and liquid chromatographic separation with quantitative tandem mass spectrometric detection (SPE-LC–MS/MS) of ximelagatran and its metabolites in a complex matrix | 1.7 | 9 | Citations (PDF) |
| 126 | Toward an Increased Understanding of the Barriers to Colonic Drug Absorption in Humans: Implications for Early Controlled Release Candidate Assessment | 3.4 | 133 | Citations (PDF) |
| 127 | Ethanol−Drug Absorption Interaction: Potential for a Significant Effect on the Plasma Pharmacokinetics of Ethanol Vulnerable Formulations | 3.4 | 57 | Citations (PDF) |
| 128 | Enterohepatic Disposition of Rosuvastatin in Pigs and the Impact of Concomitant Dosing with Cyclosporine and Gemfibrozil | 2.1 | 27 | Citations (PDF) |
| 129 | Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors | 2.6 | 22 | Citations (PDF) |
| 130 | Intestinal and Hepatobiliary Transport of Ximelagatran and Its Metabolites in Pigs | 2.1 | 18 | Citations (PDF) |
| 131 | Irregular gastrointestinal drug absorption in Parkinson's disease | 2.6 | 109 | Citations (PDF) |
| 132 | Simultaneous assessment of lipid classes and bile acids in human intestinal fluid by solid-phase extraction and HPLC methods | 2.8 | 51 | Citations (PDF) |
| 133 | Gene and Protein Expression of P-Glycoprotein, MRP1, MRP2, and CYP3A4 in the Small and Large Human Intestine | 3.4 | 181 | Citations (PDF) |
| 134 | Pharmacokinetics of gefitinib in humans: The influence of gastrointestinal factors | 4.0 | 64 | Citations (PDF) |
| 135 | Animal data: The contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery | 13.0 | 131 | Citations (PDF) |
| 136 | Presentation of a Structurally Diverse and Commercially Available Drug Data Set for Correlation and Benchmarking Studies | 4.8 | 42 | Citations (PDF) |
| 137 | Rapid modulation of Ca uptake in human jejunal enterocytes | 1.5 | 2 | Citations (PDF) |
| 138 | Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model | 2.5 | 361 | Citations (PDF) |
| 139 | A Clinical Single-Pass Perfusion Investigation of the Dynamic in Vivo Secretory Response to a Dietary Meal in Human Proximal Small Intestine | 2.5 | 62 | Citations (PDF) |
| 140 | Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase | 3.5 | 53 | Citations (PDF) |
| 141 | The effect of pancreatic and biliary depletion on the in vivo pharmacokinetics of digoxin in pigs | 3.5 | 9 | Citations (PDF) |
| 142 | FIRST-PASS EFFECTS OF VERAPAMIL ON THE INTESTINAL ABSORPTION AND LIVER DISPOSITION OF FEXOFENADINE IN THE PORCINE MODEL | 2.1 | 33 | Citations (PDF) |
| 143 | FLUTAMIDE METABOLISM IN FOUR DIFFERENT SPECIES IN VITRO AND IDENTIFICATION OF FLUTAMIDE METABOLITES IN HUMAN PATIENT URINE BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY | 2.1 | 48 | Citations (PDF) |
| 144 | The Effects of Food on the Dissolution of Poorly Soluble Drugs in Human and in Model Small Intestinal Fluids | 2.5 | 249 | Citations (PDF) |
| 145 | Transport Characteristics of Fexofenadine in the Caco-2 Cell Model | 2.5 | 114 | Citations (PDF) |
| 146 | Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatography–tandem mass spectrometry | 1.7 | 23 | Citations (PDF) |
| 147 | St John's Wort Decreases the Bioavailability of R- and S-verapamil Through Induction of the First-pass Metabolism | 2.7 | 115 | Citations (PDF) |
| 148 | Regional Intestinal Absorption and Biliary Excretion of Fluvastatin in the Rat: Possible Involvement of mrp2 | 3.4 | 35 | Citations (PDF) |
| 149 | Intestinal and blood–brain drug transport: beyond involvement of a single transport function | 3.5 | 15 | Citations (PDF) |
| 150 | Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification | 3.4 | 707 | Citations (PDF) |
| 151 | Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models | 3.5 | 65 | Citations (PDF) |
| 152 | Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver | 1.5 | 54 | Citations (PDF) |
| 153 | Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers | 3.5 | 19 | Citations (PDF) |
| 154 | In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance | 3.5 | 130 | Citations (PDF) |
| 155 | Pulmonary Absorption Rate and Bioavailability of Drugs in Vivo in Rats: Structure–Absorption Relationships and Physicochemical Profiling of Inhaled Drugs | 2.6 | 164 | Citations (PDF) |
| 156 | Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine | 2.7 | 84 | Citations (PDF) |
| 157 | Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability | 2.1 | 105 | Citations (PDF) |
| 158 | The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique | 1.5 | 72 | Citations (PDF) |
| 159 | Variable expression of CYP and Pgp genes in the human small intestine | 2.3 | 65 | Citations (PDF) |
| 160 | ABSORPTION/METABOLISM OF SULFORAPHANE AND QUERCETIN, AND REGULATION OF PHASE II ENZYMES, IN HUMAN JEJUNUM IN VIVO | 2.1 | 191 | Citations (PDF) |
| 161 | Drug Absorption from the Isolated Perfused Rat Lung–Correlations with Drug Physicochemical Properties and Epithelial Permeability | 3.0 | 91 | Citations (PDF) |
| 162 | Chemotherapy and Antiangiogenesis | 1.5 | 51 | Citations (PDF) |
| 163 | Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets | 0.8 | 231 | Citations (PDF) |
| 164 | Levodopa Pharmacokinetics and Motor Performance During Activities of Daily Living in Patients With Parkinson's Disease on Individual Drug Combinations | 0.8 | 83 | Citations (PDF) |
| 165 | Miniaturized Nebulization Catheters: A New Approach for Delivery of Defined Aerosol Doses to the Rat Lung | 1.3 | 41 | Citations (PDF) |
| 166 | High airway-to-blood transport of an opioid tetrapeptide in the isolated rat lung after aerosol delivery | 2.1 | 25 | Citations (PDF) |
| 167 | Regional differences in bioavailability of an opioid tetrapeptide in vivo in rats after administration to the respiratory tract | 2.1 | 39 | Citations (PDF) |
| 168 | The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique | 3.5 | 76 | Citations (PDF) |
| 169 | Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs | 2.5 | 404 | Citations (PDF) |
| 170 | In vitro metabolism of opioid tetrapeptide agonists in various tissues and subcellular fractions from rats | 2.1 | 11 | Citations (PDF) |
| 171 | CYP3A4, CYP3A5, and MDR1 in Human Small and Large Intestinal Cell Llines Suitable for Drug Transport Studies | 2.6 | 65 | Citations (PDF) |
| 172 | Human Jejunal Permeability of Two Polar Drugs: Cimetidine and Ranitidine | 2.5 | 63 | Citations (PDF) |
| 173 | Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans | 3.5 | 34 | Citations (PDF) |
| 174 | Stability and in vitro metabolism of dipeptide model prodrugs with affinity for the oligopeptide transporter | 3.5 | 13 | Citations (PDF) |
| 175 | Dissolution of Hydrocortisone in Human and Simulated Intestinal Fluids | 2.5 | 81 | Citations (PDF) |
| 176 | No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in rats | 1.7 | 10 | Citations (PDF) |
| 177 | SPR Biosensor Studies of the Direct Interaction between 27 Drugs and a Liposome Surface: Correlation with Fraction Absorbed in Humans | 4.8 | 127 | Citations (PDF) |
| 178 | Enantiomeric separation of verapamil and norverapamil using Chiral-AGP® as the stationary phase | 2.2 | 24 | Citations (PDF) |
| 179 | Jejunal permeability in humans invivo and rats insitu: investigation of molecular size selectivity and solvent drag | 2.2 | 78 | Citations (PDF) |
| 180 | The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans | 1.5 | 70 | Citations (PDF) |
| 181 | Surface Activity and Concentration Dependent Intestinal Permeability in the Rat | 2.5 | 14 | Citations (PDF) |
| 182 | Absorption of -DOPA from the proximal small intestine studied in the rhesus monkey by positron emission tomography. | 3.5 | 8 | Citations (PDF) |
| 183 | A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans | 3.5 | 34 | Citations (PDF) |
| 184 | Stability, metabolism and transport of -Asp(OBzl)–Ala — a model prodrug with affinity for the oligopeptide transporter | 3.5 | 21 | Citations (PDF) |
| 185 | Chitosans as absorption enhancers of poorly absorbable drugs | 3.5 | 199 | Citations (PDF) |
| 186 | Stability and perfusion studies of Desmopressin (dDAVP) and prodrugs in the rat jejunum | 2.2 | 3 | Citations (PDF) |
| 187 | High In Situ Rat Intestinal Permeability of Artemisinin Unaffected by Multiple Dosing and with No Evidence of P-glycoprotein Involvement | 2.1 | 49 | Citations (PDF) |
| 188 | Repeated Oral Rifampicin Decreases the Jejunal Permeability of R/S-Verapamil in Rats | 2.1 | 28 | Citations (PDF) |
| 189 | Jejunal Absorption and Metabolism of R/S-Verapamil in Humans | 2.5 | 90 | Citations (PDF) |
| 190 | Membrane Transport of Drugs in Different Regions of the Intestinal Tract of the Rat | 2.6 | 226 | Citations (PDF) |
| 191 | Human Intestinal Permeability | 2.6 | 431 | Citations (PDF) |
| 192 | Correlation of Human Jejunal Permeability (in Vivo) of Drugs with Experimentally and Theoretically Derived Parameters. A Multivariate Data Analysis Approach | 4.8 | 430 | Citations (PDF) |
| 193 | The pharmacokinetics and metabolism of α-trinositol (-myo-inositol 1,2,6-trisphosphate) | 3.5 | 6 | Citations (PDF) |
| 194 | Characterization of Fluids from the Stomach and Proximal Jejunum in Men and Women | 2.5 | 393 | Citations (PDF) |
| 195 | Human Intestinal Permeability of Piroxicam, Propranolol, Phenylalanine, and PEG 400 Determined by Jejunal Perfusion | 2.5 | 51 | Citations (PDF) |
| 196 | Rat Jejunal Permeability and Metabolism of μ-Selective Tetrapeptides in Gastrointestinal Fluids from Humans and Rats | 2.5 | 29 | Citations (PDF) |
| 197 | Comparison between active and passive drug transport in human intestinal epithelial (caco-2) cells in vitro and human jejunum in vivo | 4.0 | 257 | Citations (PDF) |
| 198 | Comparison Between Permeability Coefficients in Rat and Human Jejunum | 2.5 | 385 | Citations (PDF) |
| 199 | Jejunal permeability and hepatic extraction of fluvastatin in humans | 2.7 | 75 | Citations (PDF) |
| 200 | Permeability and clearance views of drug absorption: A commentary | 0.7 | 20 | Citations (PDF) |
| 201 | A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability | 2.5 | 4,686 | Citations (PDF) |
| 202 | Regional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man | 2.5 | 96 | Citations (PDF) |
| 203 | Does Fluid Flow Across the Intestinal Mucosa Affect Quantitative Oral Drug Absorption? Is It Time for a Reevaluation? | 2.5 | 99 | Citations (PDF) |
| 204 | The Lack of Effect of Induced Net Fluid Absorption on the in vivo Permeability of Terbutaline in the Human Jejunum | 3.0 | 46 | Citations (PDF) |
| 205 | Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption | 3.5 | 100 | Citations (PDF) |
| 206 | The Influence of Net Water Absorption on the Permeability of Antipyrine and Levodopa in the Human Jejunum | 2.5 | 40 | Citations (PDF) |
| 207 | Pharmacokinetics of Levodopa and Carbidopa in Rats Following Different Routes of Administration | 2.5 | 44 | Citations (PDF) |
| 208 | Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat. | 1.5 | 91 | Citations (PDF) |
| 209 | P46 Ionic constituents; pH and osmolality of gastric and small intestine fluids in man | 3.5 | 0 | Citations (PDF) |
| 210 | P47 Transport of levodopa across the blood-brain barrier measured by microdialysis | 3.5 | 0 | Citations (PDF) |
| 211 | FC29 permeability of drugs with different physico-chemical properties in the human jejunum and Caco-2 monolayers | 3.5 | 0 | Citations (PDF) |
| 212 | Gastrointestinal absorption mechanisms: a comparison between animal and human models | 3.5 | 16 | Citations (PDF) |
| 213 | Dose-Dependent Intestinal Absorption and Significant Intestinal Excretion (Exsorption) of the β-Blocker Pafenolol in the Rat | 2.5 | 39 | Citations (PDF) |
| 214 | Evidence for an Interaction Between the β-Blocker Pafenolol and Bile Salts in the Intestinal Lumen of the Rat Leading to Dose-Dependent Oral Absorption and Double Peaks in the Plasma Concentration–Time Profile | 2.5 | 75 | Citations (PDF) |
| 215 | Regional Gastrointestinal Absorption of the Beta-Blocker Pafenolol in the Rat and Intestinal Transit Rate Determined by Movement of 14C-Polyethylene Glycol (PEG) 4000 | 2.5 | 36 | Citations (PDF) |
| 216 | The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. | 1.5 | 99 | Citations (PDF) |
| 217 | Presystemic elimination of the beta-blocker pafenolol in the rat after oral and intraperitoneal administration and identification of a main metabolite in both rats and humans. | 2.1 | 10 | Citations (PDF) |
| 218 | Regional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man | 2.5 | 198 | Citations (PDF) |
| 219 | ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium | 3.4 | 26 | Citations (PDF) |
| 220 | Integrated Physiologically-Based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 1: Model Development and Validation | 2.2 | 1 | Citations (PDF) |
| 221 | Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives | 3.4 | 7 | Citations (PDF) |
| 222 | The Evolving Role of In Vitro–In Vivo Correlation in Model-Informed Drug Development: A Multi-Stakeholder Perspective | 1.6 | 4 | Citations (PDF) |
| 223 | Integrated Physiologically-based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 2: MIDD and MIPD Applications | 2.2 | 0 | Citations (PDF) |
| 224 | A comparative study of idarubicin and doxorubicin in a chemically-induced mouse model for hepatocellular carcinoma | 5.7 | 3 | Citations (PDF) |
| 225 | CombiCTx: screening diffusion gradients of anti-cancer drug combinations | 4.2 | 0 | Citations (PDF) |
| 226 | From bench to bedside: biopharmaceutics tools for smarter drug development 0, 2026, e1011024 | | 0 | Citations (PDF) |
| 227 | Formulation breakthroughs driving broader tyrosine kinase use | 1.5 | 0 | Citations (PDF) |
| 228 | Letter to the Editor Regarding "The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants" Recently Published by Tran and Colleagues. | 1.9 | 4 | Citations (PDF) |
| 229 | Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling. | 1.6 | 0 | Citations (PDF) |
| 230 | The In Vivo Effect of Amorphous Drug Nanoprecipitates on the Intestinal Absorption of the PROTACs ARV-110 (Bavdeglutamide) and ARV-471 (Vepdegestrant). | 3.4 | 3 | Citations (PDF) |
| 231 | Inhibition of PERK signaling suppresses tumor progression and blocks GP73-GRP78-dependent stromal activation in hepatocellular carcinoma. | 3.0 | 1 | Citations (PDF) |
| 232 | Column coupling for chiral LC-MS separation resolves triacylglycerol enantiomers and regioisomers in complex samples without flow recycling. | 5.0 | 0 | Citations (PDF) |
| 233 | Characterization of hepatocellular carcinoma patient-derived organoids from patients receiving transarterial chemoembolization as a model for preclinical drug response assessment. | 2.8 | 0 | Citations (PDF) |
| 234 | Effects of intestinal permeation enhancers on solubilization and epithelial transport of the proteolysis targeting chimera (PROTAC) ARV-471 in rats. | 8.5 | 0 | Citations (PDF) |
